Granules India Q2 FY24 PAT drops 30% at Rs. 102 Cr

Sales in the US region grew well, partially offset by the decline in the LATAM and European regions

Glenmark Pharma reports Q2 FY24 loss at Rs. 62 Cr

European operations' revenue grew 58.4% to Rs 599.7 crore

Marksans Pharma posts Q2 FY24 consolidated PAT at Rs. 82.7 Cr

US business grew by +12.8% YoY

SMS Pharmaceuticals reports robust Q2FY24 operational performance

Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore

Bayer posts Q3 2023 Group sales Euro 10.34 billion

We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”

Supriya Lifescience reports Q2 FY24 PAT higher 42% at Rs. 23.88 Cr

Pfizer posts Q3 loss as Covid-19 revenues shrink

Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion

Lubrizol launches carbopol polymers for nutraceuticals with new EU good grade approval

The European Commission approved the use of Carbopol as an additive for liquid and solid food supplements in the EU

Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr

Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter

Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced non-small cell lung cancer

Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients